We believe this site might serve you best::

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

VivoGlo™ Caspase 3/7 Substrate (Z-DEVD-Aminoluciferin Sodium Salt)

Firefly Luciferase Prosubstrate Recognized and Cleaved by Caspase-3 and -7

  • High-quality substrate eliminates potential interference in assays due to the presence of endotoxins
  • Available in multiple sizes to accommodate a variety of experimental settings

Size

Catalog number selected: P1781

$ 1,151.00 Your price: Log In

VivoGlo™ Caspase 3/7 Substrate (Z-DEVD-Aminoluciferin Sodium Salt)
50mg
$ 1,151.00
Your price: Log In
Change Configuration

VivoGlo™ Caspase-3/7 Substrate (Z-DEVD-Aminoluciferin, Sodium Salt) is a firefly luciferase prosubstrate containing the DEVD tetrapeptide sequence recognized by caspase-3 and -7. Upon activation of caspase-3 or -7, the DEVD peptide is cleaved, and the liberated aminoluciferin reacts with luciferase to generate measurable light. Cleavage has been shown in in cellulo and in vivo systems. For mice, activity of a related salt was demonstrated when 10mg of the substrate in 150μl of saline was injected intraperitoneally. Other references suggest that doses as low as 1.5mg per mouse (50mg/kg) can be used. We recommend conducting a preliminary dose-response study using no more than 500mg/kg.

VivoGlo™ Caspase-3/7 Substrate (Z-DEVD-Aminoluciferin, Sodium Salt) has a minimum solubility of 500mg/ml in PBS, and the resulting solution is stable for at least 3 days at room temperature. Injection is usually done via the intraperitoneal route, and imaging is generally started 10 minutes after injection. Product integrity is ensured by packaging most products in amber vials with septa as well as offering ease of dilution and use for imaging experiments. VivoGlo™ Caspase-3/7 Substrate is packaged with fine tolerances to minimize the need to weigh substrates.

References

  1. Liu, J.J. et al. (2005) Cancer Biol. Ther. 4(8), 885 92.
  2. Shah, K. et al. (2005) Mol. Ther. 11(6), 926 31.
  3. Kizaka-Kondoh, S. et al. (2009) Clin. Cancer Res. 15, 3433 41.
  4. Scabini, M. In vivo imaging of early stage apoptosis measuring real-time caspase-3 activation. Presentation at: 4th European Molecular Imaging Meeting; 2009 May 27 30, Barcelona, Spain.

Protocols

Specifications

You are viewing: 50mg Change Configuration

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Specifications

You are viewing: 5 × 50mg Change Configuration

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Resources

Choose your country

Americas

Brazil
Brazil
Canada
Canada
United States
United States

Pacific Asia

Australia
Australia
India
India
Japan
Japan
Korea, Republic of
Korea, Republic of
Singapore
Singapore

Europe

Austria
Austria
Belgium
Belgium
Denmark
Denmark
Estonia
Estonia
Finland
Finland
France
France
Germany
Germany
Iceland
Iceland
Italy
Italy
Luxembourg
Luxembourg
Netherlands
Netherlands
Norway
Norway
Poland
Poland
Spain
Spain
Sweden
Sweden
Switzerland
Switzerland
United Kingdom
United Kingdom